Home Covid19 Study: COVID Immunity is ‘Forever’

Study: COVID Immunity is ‘Forever’

by Paul Ebeling

#COVID #infection #immunity #antibodies

Research has found that people who have had mild cases of COVID-19 retain immune cells that pump out antibodies that protect against the COVID-19 causing virus months after recovering.  

These immune cells could continue to persist for life, making antibodies all of the time.  

The study results indicate that mild cases of COVID-19 provide long-lasting antibody protection and that recurring bouts of illness are unlikely to be common”— Paul Ebeling

There were reports in the Autumn of Y 2020 that antibodies would diminish rapidly following infection with the virus that leads to COVID-19, and it was construed by the MSM to suggest that immunity was not long-lived, which was a misinterpretation of the data.

It is common for levels of antibodies to drop following an acute infection, they however plateau as opposed to dropping to Zero.

In this study, cells that produce antibodies were found in individuals 11 months following their 1st symptoms. These immune cells will continue producing antibodies for the remainder of their lives, and is solid proof for ‘forever’ immunity.

Immune cells that produce antibodies quickly circulate and multiply in the blood during a viral infection, which drives levels of antibodies sky-high.

Most of these immune cells die off as soon as the infection is over, and antibody levels decline. A small amount of cells that produce antibodies, known as long-lived plasma cells, then migrate to the bone marrow where they remain.

There they are constantly secreting low levels of antibodies in to the blood to help in protecting against another attack from the virus. The answer to finding out if COVID-19 results in enduring antibody protection lies in the bone marrow.

The researchers obtained bone marrow from 18 individuals 7 or 8 months after their initial mild cases of COVID-19infections to determine if they have long-lived plasma cells which produce antibodies that are specifically targeted to the virus that leads to COVID-19 known as SARS-CoV-2. And 5 of the individuals returned 4 months later and gave a 2nd sample of bone marrow. Bone marrow was also acquired from 11 individuals who had never been infected with COVID-19 for comparison.

The antibody blood levels of the COVID-19 individuals dropped rapidly in the 1st few months following infection and then typically plateaued, with a quantity of antibodies detected 11 months following infection.

Additionally, 15 of the 19 bone marrow samples taken from individuals who had been infected with COVID-19 had antibody-producing cells that are specifically targeting the virus that results in COVID-19 infection.

These antibody producing cells could still be detected 4 months afterwards in the 5 people who returned to give a 2nd bone-marrow sample. The antibody-producing cells were not detected in the bone marrow of any of the 11 individuals who did not have COVID-19.

The virus is cleared from the bodies of individuals suffering from mild cases of COVID-19 two to three wks following infection, and there would not be any virus generating an active immune response 7 or 11 months following infection.

These cells are quiescent, they just sit in the bone marrow and secrete antibodies. They have been doing that from the time the infection went away, and they will continue secreting antibodies indefinitely. The researchers theorized that individuals who had been infected and did not have symptoms may also have long-lasting immunity

Eat healthy, Be healthy, Live lively

You may also like


Your Trusted Source for Capital Markets & Related News

© 2023 LiveTradingNews.com – For The Traders, By The Traders – All Right Reserved.

The information contained on this website shall not be construed as (i) an offer to purchase or sell, or the solicitation of an offer to purchase or sell, any securities or services, (ii) investment, legal, business or tax advice or an offer to provide such advice, or (iii) a basis for making any investment decision. An offering may only be made upon a qualified investor’s receipt not via this website of formal materials from the Knightsbridge an offering memorandum and subscription documentation (“offering materials”). In the case of any inconsistency between the information on this website and any such offering materials, the offering materials shall control. Securities shall not be offered or sold in any jurisdiction in which such offer or sale would be unlawful unless the requirements of the applicable laws of such jurisdiction have been satisfied. Any decision to invest in securities must be based solely upon the information set forth in the applicable offering materials, which should be read carefully by qualified investors prior to investing. An investment with Knightsbridge is not suitable or desirable for all investors; investors may lose all or a portion of the capital invested. Investors may be required to bear the financial risks of an investment for an indefinite period of time. Qualified investors are urged to consult with their own legal, financial and tax advisors before making any investment. Knightsbridge is a private investment firm that offers investment services to Qualified Investors, Members and Institutions ONLY. Qualified Investors are defined as individuals who have met those Qualifications in the relevant jurisdictions. Members are defined as individuals who have been accepted into the Knightsbridge membership program. Institutions are defined as entities such as banks, pension funds, and hedge funds. If you are not a Qualified Investor, Member or Institution, you are not eligible to invest with Knightsbridge. All investments involve risk, and there is no guarantee of profit. You may lose some or all of your investment. Past performance is not indicative of future results. Knightsbridge is not a registered investment advisor, and this disclaimer should not be construed as investment advice. Please consult with a qualified financial advisor before making any investment decisions. By accessing this website, you agree to the terms of this disclaimer. Thank you for your interest in Knightsbridge.